Clinical Trial Update: 4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures [Phase 2]

View source ↗

Summary

The four-year open-label extension of a Phase 2 study evaluating E2007 in patients with refractory partial seizures has completed, and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• E2007

Snippet

Sponsor: Eisai Inc. | Conditions: Epilepsy | Phase 2 | Status: COMPLETED | Results posted: 2015-12-10